The agency focuses its oversight on removing unsafe products from the market and ensuring labels arent false or misleading
Last Published 12.01.2025 Effective Date: 12.01.2025 This policy addresses the use of Zolgensma (onasemnogene abeparvovec-xioi) for the treatment of spinal muscular atrophy (SMA)
The Lack of Fit value, representing the discrepancy between the model and the observed data, is determined to be not significant with a p-value of 0.1142
With its unique formulation and potential benefits, this cream has become a sought-after solution for individuals looking to lighten their skin tone
The effects that sit outside the trial tables Menstrual-cycle changes are widely discussed in patient communities, including irregular or doubled cycles during rapid loss. Trials did not pre-specify them, so the adverse-event tables cannot estimate incidence
Healthier Substitute Fresh or frozen fruit can help satisfy a sweet tooth, says Tucker